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Is interleukin-1b a culprit in macrophage-adipocyte crosstalk in obesity?
Chen Bing
Department of Obesity and Endocrinology, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK
Adipose tissue remodeling occurs inobesity, characterized by adipocyte
hypertrophy and increased infiltration of
macrophages which also shift to a proin-
flammatory phenotype. Factors derived
from these macrophages significantly
alter adipocyte function, such as repres-
sing adipogenesis, inducing inflamma-
tory response and desensitizing insulin
action. As macrophages produce a cock-
tail of inflammatory signals, identifying
the key factors that mediate the detri-
mental effects may offer effective thera-
peutic targets. IL-1b, a major cytokine
produced largely by macrophages, is
implicated in the development of obe-
sity-associated insulin resistance. In this
article, we discuss recent advances in our
understanding of the role of IL-1b in
macrophage-adipocyte crosstalk in obe-
sity. IL-1b impairs insulin sensitivity in
adipose tissue by inhibition of insulin
signal transduction. Blocking the activity
of IL-1b, its receptor binding or produc-
tion improves insulin signaling and
action in human adipocytes. This is in
parallel with a reduction in macrophage-
stimulated proinflammatory profile and
lipolysis. Targeting IL-1b may be benefi-
cial for protecting against obesity-related
insulin resistance at the tissue and sys-
temic levels.
Adipose Tissue Remodeling
in Obesity
Central obesity has a close link to the
development of ‘metabolic syndrome’
manifested by insulin resistance, glucose
intolerance, dyslipidemia and hyperten-
sion.1 The metabolic derangements pre-
dispose to the development of type 2
diabetes and cardiovascular diseases.1
Although the pathophysiology of obesity-
associated metabolic disorders is complex,
evidence suggests that chronic low-grade
inflammation in white adipose tissue plays
a role.2-4 Adipose tissue is composed of
mature adipocytes (»50%) and other cells
(»50%) from the stromal vascular
fraction (SVF) which con-
tains preadipocytes, fibroblasts, endothe-
lial cells and immune cells (i.e.
macrophages, lymphocytes, mast cells,
dendritic cells, eosinophils).5,6 The plas-
ticity of adipose tissue provides a mecha-
nistic base for its pleiotropic functions
that influence lipid, endocrine, and
immune homeostasis. However, over-
nutrition in obesity triggers adipose tissue
remodeling that the tissue becomes a site
of inflammation. In addition to adipocyte
hypertrophy, there is a marked accumula-
tion of macrophages together with other
immune cells in adipose tissue.2,7,8 The
proportion of macrophages in the SVF is
estimated to be increased from »10%
in lean to »40-50% in obese adipose
tissue.9 Furthermore, obesity induces a
phenotypic switch from the M2 macro-
phages (producing anti-inflammatory
cytokines) to the M1 macrophages (pro-
ducing pro-inflammatory cytokines), asso-
ciated with insulin resistance both in mice
and humans.10-12 Factors derived from
macrophages also influence adipose tissue
biology, such as inhibiting adipogenesis,
modulating adipokine production, and
mounting inflammatory responses.13-18
Macrophage-Adipocyte crosstalk on
insulin signaling in adipose tissue
In addition to skeletal muscle and liver,
adipose tissue is a key organ that responds
to insulin action.19 In obesity the lowered
insulin sensitivity in adipocytes could
stimulate lipolysis and fatty acid release
into the circulation, leading to ectopic fat
deposition and ultimately systemic insulin
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resistance.20 Insulin action requires the
activation of insulin signaling pathway;
IRS1, one of the major substrates of the
insulin receptor, is essential to activate
PI3K in response to insulin, which leads
to the phosphorylation of protein kinase B
(also known as Akt) resulting in an
increase in GLUT4 transporters in the
plasma membrane.21 The enhanced mac-
rophage-adipocyte crosstalk in obesity,
including macrophage-derived factors, has
been shown to disrupt insulin action in
murine 3T3-L1 adipocytes.22 However,
whether it occurs in human adipose tissue
together with the potential mediators and
mechanisms are largely unknown. Our
recent study examined the impact of sig-
nals derived from human macrophages on
insulin signaling in human adipocytes.23
We observed that macrophage-derived
factors impair insulin signaling in human
adipocytes as macrophage-conditioned
(MC) medium inhibited gene and protein
expression of insulin signaling molecules,
including IRS1, PI3K p85a, GLUT4 and
the phosphorylation of Akt. In contrast,
the expression and release of the proin-
flammatory markers (i.e. IL-6, IL-8,
MCP-1, CCL-5) by adipocytes were
markedly increased.
IL-1b and insulin resistance
Identification of the major factors that
mediate the detrimental effect of macro-
phages on adipocytes is challenging but it
may offer potential therapeutic targets.
Several macrophage-secreted factors are
implicated in metainflammation, includ-
ing TNFa and IL-6. TNFa has been
shown to induce insulin resistance in
rodents and block insulin actions in 3T3-
L1 adipocytes.22, 24-26 Using human prea-
dipocytes, neutralization of TNFa attenu-
ated macrophage-stimulated increase in
IL-6 mRNA while had a modest effect on
adipogenic marker aP2.16 In our recent
study, simultaneously blocking TNFa
and IL-1b had no additive effect on the
expression of insulin signaling proteins.23
IL-6 was found to be overexpressed in fat
cells from insulin-resistant subjects and
induce insulin resistance in 3T3-L1 adipo-
cytes.27 It remains to be investigated
whether IL-6 acts as a key mediator in
macrophage-adipocyte crosstalk. Macro-
phage-derived IL-1F6 and IL-1F8,
members of the IL-1 family, was reported
to stimulate gene expression of IL-6 and
IL-8 in mature human adipocytes albeit
both are less potent than IL-1b.28 The
involvement of IL-1F6 and IL-1F8 in
adipose tissue inflammation and insulin
sensitivity in obesity is not yet known.
IL-1b, a major proinflammatory cyto-
kine, is produced mostly by macrophages
and biologically active IL-1b is formed
through cleavage of pro-IL-1b by caspase-
1 activated via the NLRP3 inflamma-
some.29 IL-1b production by adipose tis-
sue macrophages is caspase-1-dependent
in humans.30 Growing evidence suggests
that IL-1b is critically involved in the
translation of obesity-associated inflam-
mation into insulin resistance in rodent
models.31,32 IL-1b is also released by
human adipose tissue but primarily from
the nonfat cells, and the release is
enhanced in obesity.33,34 High dose of
IL-1b (20 ng/ml) has been shown to
decrease protein expression of IRS-1 and
GLUT4 mRNA in murine 3T3-L1 adipo-
cytes.35, 36 Our recent work demonstrated
that in human adipocytes IL-1b at a lower
dose (2 ng/ml) repressed insulin signal
transduction by reducing the expression of
signaling (i.e. IRS1, PI3K p85a, pAkt)
and glucose transporter (GLUT4) pro-
teins.23 We also found in a previous study
that macrophage-induced production of
matrix metalloproteinase 1 and 3 by prea-
dipocytes is mediated by IL-1b.37 These
findings suggest that IL-1b could have a
central role in macrophage-adipocyte
crosstalk which blocks insulin action in
human adipose tissue.
IL-1b as a mediator of macrophage-
adipocyte crosstalk
In our recent work, we showed that IL-
1b is required for the inhibitory effect of
macrophages on insulin signaling in
human adipocytes.23 Blocking IL-1b
activity, with a neutralizing antibody, sub-
stantially reduced effects of MC medium
on expression profile of genes involved in
insulin signaling, insulin sensitivity and
glucose metabolism in adipocytes. Fur-
thermore, IL-1b depletion abolished mac-
rophage-induced inhibition on expression
of insulin signaling proteins (IRS1, PI3K
p85a and GLUT4 and Akt phosphoryla-
tion) and glucose consumption,
suggesting that IL-1b blockade can restore
insulin signal transduction in human adi-
pocytes. This was supported by the data
that inhibition of IL-1b receptor binding
in adipocytes with an IL-1 receptor antag-
onist (IL-1Ra) restored expression of sig-
naling and glucose transport proteins
suppressed by MC medium. To substanti-
ate the importance of IL-1b in MC
medium, we used a caspase-1 inhibitor to
block IL-1b production by macrophages.
The protein expression of insulin signaling
molecules was partially (for IRS1, PI3K
p85a) or totally (for GLUT4) reversed in
adipocytes exposed to the MC medium.
This is in parallel with the attenuation of
macrophage-stimulated proinflammatory
profile and lipolysis.
Although the mechanisms by which
IL-1b mediates macrophage-adipocyte
crosstalk desensitizing insulin action
remain to be clarified, local inflammation
in adipose tissue could be vital.4 It is evi-
dent that macrophage-derived factors
potently stimulate the production of
proinflammatory cytokines/chemokines
(i.e. IL-6, MCP-1, CCL5, IL-8) by adipo-
cytes as well as preadipocytes.16,23,38 The
overproduction of chemoattractants may
promote monocyte migration and M1
macrophages polarization.39-42 Cytokine
IL-6 and TNFa are known to reduce
insulin signaling and insulin-stimulated
glucose uptake in 3T3-L1 adipocytes.24-27
Interestingly, we observed that overpro-
duction of proinflammatory markers can
be largely reversed by antagonizing IL-1b
activity, IL-1 receptors or blocking IL-1b
production.23 Thus, the detrimental
effects of macrophage-derived IL-1b on
insulin signaling in adipocytes could be
mediated via upregulated inflammatory
responses, especially over-production of
proinflammatory cytokines/chemokines
(Fig. 1).
Targeting IL-1b in obesity
In rodent models of obesity and diabe-
tes, blocking IL-1b reduces hyperglycemia
and tissue inflammation.43-46 In patients
with type 2 diabetes, IL-1b antagonism or
IL-1 receptor antagonist (anakinra) also
show beneficial effects on glucose control
and b-cell function, with a reduction in
circulating proinflammatory markers.47-49
Since adipose tissue inflammation links
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obesity to insulin resistance, studies on the
tissue specific effects of IL-1b inhibition
in humans are required. Targeting IL-1b
might put a brake on the vicious cycle of
macrophage infiltration and escalated
inflammatory response in adipose tissue,
thereby improving insulin sensitivity at
tissue and also systemic levels.
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